title: Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis.
authors.forename: Farzin
authors.initials: F
authors.lastname: Forooghian
authors.forename: Emily Y
authors.initials: EY
authors.lastname: Chew
authors.forename: Catherine B
authors.initials: CB
authors.lastname: Meyerle
authors.forename: Catherine
authors.initials: C
authors.lastname: Cukras
authors.forename: Wai T
authors.initials: WT
authors.lastname: Wong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000097:blood*; D000068258:Bevacizumab; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy / Q000276:immunology; D008297:Male; D011446:Prospective Studies; D011817:Rabbits; D013618:Tachyphylaxis / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab